The Federal State Unitary Enterprise “Moscow Endocrine Plant” holds a certification for the medication “Rivastigmine-ET” (rivastigmine), available as a transdermal patch with release rates of 4.6 mg/24h, 9.5 mg/24h, and 13.3 mg/24h. The medication is designed to treat mild, moderate, and severe dementia associated with Alzheimer’s disease in adults aged 18 and older.
Transdermal dosage forms offer several advantages over oral and parenteral routes of administration, including a decrease in the frequency of medication needed, as well as a reduction in the risk of adverse reactions and misuse.
